logo
Fisherman hooks ‘aggressive' predator in first-of-its-kind catch in Chile. See it

Fisherman hooks ‘aggressive' predator in first-of-its-kind catch in Chile. See it

Miami Herald24-04-2025

In a fjord along the coast of southern Chile, a fisherman hauled in an 'aggressive' ocean predator and brought it to a nearby dock. The animal caught the attention of visiting scientists — and for good reason.
It turned out to be a first-of-its-kind catch.
Comau Fjord is a 'deep and narrow' inlet connected to the Pacific Ocean and the site of a poorly understood phenomenon: 'the occurrence of deepwater species in shallow depths, far beyond their usual distributional range,' according to a study published April 15 in the peer-reviewed Journal of the Marine Biological Association of the United Kingdom.
A team of researchers suspected Comau Fjord had more shark and skate diversity than previously realized so they spent six months in 2018 surveying its depths, the study said.
To do so, researchers set up longline fishing gear at several locations around the fjord, let the lines sink down to roughly 1,500 feet and waited. Any animals they caught were photographed, sampled for DNA and then released. The team also spoke to local fishermen and SCUBA divers.
Their efforts paid off. Overall, researchers documented nine species of shark, skate and dogfish, including three species recorded in the fjord for the first time.
One of these new records was the broadnose sevengill shark, or Notorynchus cepedianus, the study said. Photos show two of these shark sightings, which included an encounter by a SCUBA diver caught on video and a catch made by a local fisherman.
Broadnose sevengill sharks are 'large,' 'opportunistic' predators considered 'aggressive when provoked' and 'potentially dangerous to humans,' according to the Florida Museum. The species is vulnerable and has been 'used for human consumption, liver oil and leather' for decades.
Researchers documented another first-of-its-kind catch of several yellownose skates, or Dipturus chilensis, the study said. Photos show these endangered skates.
Other photos show a largespine velvet dogfish, or Scymnodon macracanthus, found at the fjord for the first time, the study said.
Researchers also recorded several more species of shark, including the endangered leafscale gulper shark, more species of dogfish and another skate species. In total, seven of the nine recorded species were considered at-risk and had shrinking populations.
The team concluded that Comau Fjord is an important habitat for several deep-water species and may serve as a 'primary nursery ground' for some. They described their work as 'essential data to inform decision makers, conservation managers, and future research' and suggested further wildlife surveys.
A 2017 YouTube video shared by Camilo S. shows Comau Fjord, located along the southwestern coast of Chile.
The research team included Mette Schiønning, Lara Marcús, Ana Veríssimo, Aris Thomasberger, Stacy Ballyram, Günter Försterra and Francisco Concha.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Meet the 19-year-old director who just got an A24 deal
Meet the 19-year-old director who just got an A24 deal

Yahoo

time10 hours ago

  • Yahoo

Meet the 19-year-old director who just got an A24 deal

Independent film distributor A24 has just given a 19-year-old filmmaker the green light for his first studio feature. Kane Parsons will direct the sci-fi/horror concept The Backrooms for A24, with Chiwetel Ejiofor and Renate Reinsve set to star. Variety described the upcoming film as "based on the world of Parsons' viral YouTube horror universe." So who is Parsons, you might ask? The young filmmaker describes himself on his YouTube page, Kane Pixels, as a "19 Trillion-Year-Old Director and VFX artist." He can now add A24 director to that biography. We'll see if Parsons is the next major talent to emerge from the A24 pipeline once his first feature is complete. Early returns seem quite promising with one of the most popular distributors in the world by his side. This article originally appeared on For The Win: Meet the 19-year-old director who just got an A24 deal

Summer Snake Series: Dusty pygmy rattlesnake is on Florida's venomous list
Summer Snake Series: Dusty pygmy rattlesnake is on Florida's venomous list

Yahoo

time21 hours ago

  • Yahoo

Summer Snake Series: Dusty pygmy rattlesnake is on Florida's venomous list

There are more than 40 species of snakes that are native to Florida, but only six of them are venomous. This week The News-Press and Naples Daily News is taking a closer look at each of these snakes for a special series. Snakes are most active in the spring and early summer months, when the weather warms up and they emerge from brumation, which is similar to hibernation. As it starts to heat up for the summer in Florida, you might see more of your slithery neighbors gliding through your grass or across your driveway. But not every snake is a threat. Here's a closer look at today's featured venomous snake: Dusky pygmy rattlesnakes, also known as pygmy rattlesnakes, have a dark or light gray body, with row of black or charcoal blotches along the length of its body and a reddish-brown stripe running down the middle of the back. Their bites are very painful, but not life-threatening. They can be found throughout the entire state, but aren't known to occur in the Florida Keys, according to the Florida Museum. According to the University of Florida IFAS website, these snakes live in natural wooded areas but can sometimes be found in neightborhoods. To see photos and more in-depth descriptions on these and Florida's native, harmless snakes, visit the Florida Museum's guide for identifying the state's snakes. This article originally appeared on Naples Daily News: Is Florida's Dusty pygmy rattlesnake venomous?

BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS)
BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS)

Yahoo

timea day ago

  • Yahoo

BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS)

Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of inflammatory diseases, to be studied as an intervention for the negative outcomes of decompression in SCUBA Divers NORTH BRUNSWICK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for acute and chronic inflammatory diseases, announces that it will conduct a Phase 2 study of rhu-pGSN for decompression sickness (DCS) under a contract awarded by the U.S. Navy's Office of Naval Research to the University of Maryland School of Medicine (UMSOM). This work is the culmination of an extended collaboration with Dr. Stephen Thom, Professor of Emergency Medicine at UMSOM. The Company's portfolio is built around gelsolin, a highly conserved and critical immune regulatory protein which rebalances dysfunctional inflammation without suppressing immune function. Phase 2 Clinical Trial of Rhu-pGSNThe study, 'Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers,' NCT06216366 is being conducted under a contract with the Office of Naval Research with the University of Maryland. It will investigate the use of rhu-pGSN as a pre- or post-exposure intervention in healthy trained SCUBA divers exposed to controlled hyperbaric conditions. The study is designed to assess the impact of rhu-pGSN on key inflammatory responses and microparticle production associated with decompression. Decompression sickness occurs when inert gas bubbles form in the bloodstream and tissues due to rapid pressure changes, triggering an inflammatory cascade. Previous studies have shown that individuals with DCS exhibit depleted levels of plasma gelsolin and elevated levels of microparticles that contain inflammatory cytokines. In animal models, supplementation with rhu-pGSN both prevented and mitigated DCS-related complications. This randomized, double-blind, placebo-controlled study will enroll healthy trained SCUBA divers at a single site and expose them to a standardized hyperbaric protocol (30 meters of seawater for 35 minutes). Participants will be randomized into three groups to receive either pre-exposure or post-exposure rhu-pGSN, or placebo. The study will assess a broad range of outcomes including plasma gelsolin levels, inflammatory markers like IL-1β, gas bubble formation, and well-being metrics. Dr. Thom states, 'If successful, this study could transform the way we manage decompression sickness by providing a portable, field-deployable treatment option. Reducing our reliance on hyperbaric chambers would greatly expand our ability to treat DCS in remote or operational environments, improving outcomes and readiness, a key goal for the Navy.' BioAegis and University of Maryland are co-applicants on a patent filing listing Dr. Thom as an inventor. Gelsolin: A Multitasking Protein for Complex Inflammatory ConditionsRhu-pGSN holds immense promise as a therapeutic intervention for serious acute and chronic conditions due to its multifaceted mechanism of action. In critical illness, gelsolin levels collapse, causing adverse outcomes. Supplementing gelsolin addresses this deficit directly, restoring immune balance while preserving host defense and rhu-pGSN has been shown in animal studies to: Modulate the activation of the NLRP3 inflammasome. Enhance uptake and killing of microbial pathogens by innate immune cells. Bind to and remove harmful inflammatory mediators and toxic actin released from damaged cells. Regulate macrophage phenotype to modulate inflammation. Supplementation with the recombinant gelsolin protein holds promise to address the overzealous inflammatory response associated many inflammatory diseases without suppressing immune function. About BioAegisBioAegis Therapeutics Inc. is a NJ-based clinical-stage private company whose mission is to capitalize on a key regulatory component of the body's immune system, plasma gelsolin, to prevent adverse outcomes in diseases driven by inflammation. BioAegis has the exclusive license to broad, worldwide intellectual property through Harvard-Brigham and Women's Hospital. It holds over 40 patents issued for coverage of inflammatory disease, infection, renal failure, neurologic disease, and frailty. BioAegis will also have U.S. biologics exclusivity and has recently filed new IP in areas of unmet need. BioAegis' lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS). This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00067. NCT05947955 Investor Inquiries:Steven Cordovano203-952-6373scordovano@ Media Inquiries:Christine Laganaclagana@ This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management's plans, objectives, and strategies. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store